For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
|
| Basic information |
| Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
| Ou Keng-Liang |
Ou Keng-Liang |
Chan Yu-Hao |
02-2697-1270 |
21F.-1, No. 99, Sec. 1, Xintai 5th Rd., Xizhi Dist.New Taipei City 221, Taiwan |
2020/12/25 |
| Industrycategory |
Key businesses |
| Biotechnology and Medical Care |
The research and development priorities of 3D Global Biotech Inc. are consistent with the government's, focusing on “medical services.” We uphold the spirits of honesty, responsibility and service, and is in line with the government’s policy to develop the cutting-edge medical devices as our main objective. Our three main research focuses of medical devices are medical materials for reconstruction of human tissues and organs (regeneration of soft and hard tissues), evaluation models of human tissues and organs (digital image reverse engineering) and bio-ink (cell printing). We combine these three technologies to develop into an integrated healthcare system to become Taiwan's first high-end medical material company, which prints cells with 3D printing technology and conducts clinical trials of tissue and organ reconstruction. Our main products are CLASS II medical devices, including SmileAlign Orthodontic Aligner System and α-Former bone graft substitute. |
| Financial data |
| Cash flows statement
| Item
|
|
|
| Amount(NTD, in thousands) |
| Cash flows from operating activities |
|
|
| Cash flows from investing activities |
|
|
| Cash flows from financing activities |
|
|
Consolidated/Individual
balance sheet
|
Current assets |
|
|
| Non-current assets |
|
|
| Total assets |
|
|
| Current liabilities |
|
|
| Non-current liabilities |
|
|
| Total liabilities |
|
|
| Share capital |
|
|
| Capital surplus |
|
|
| Retained earnings |
|
|
| Other equity interest |
|
|
| Treasury shares |
|
|
| Total equity attributable to owners of parent |
|
|
| Non-controlling interests |
|
|
| Total equity |
|
|
| Book Value per share(NT$) |
|
|
Consolidated/Individual
profit and loss
statement |
Operating revenue |
|
|
| Operating costs |
|
|
| Gross profit from operations |
|
|
| Operating expenses |
|
|
| Net other income (expenses) |
|
|
| Net operating income |
|
|
| Non-operating income and expenses |
|
|
| Profit before tax |
|
|
| Tax expense |
|
|
| Profit from continuing operations |
|
|
| Profit from discontinued operations |
|
|
| Profit |
|
|
| Other comprehensive income |
|
|
| Comprehensive income |
|
|
| Basic earnings per share |
|
|
 Auditor's report on latest financial statements： auditor's report：
|
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|
